



LAHIVE
&
COCKFIELD
L L P

COUNSELLORS AT LAW
28 STATE STREET
BOSTON, MASSACHUSETTS 02109-1784
TELEPHONE (617) 227-7400
FAX (617) 742-4214
lc@lahive.com

JOHN A. LAHIVE, JR. (1928-1997)
THOMAS V. SMURZYNSKI
RALPH A. LOREN
GIULIO A. DeCONTI, JR.
ANN LAMPORT HAMMITTE
ELIZABETH A. HANLEY
AMY BAKER MANDRAGOURAS
ANTHONY A. LAURENTANO
KEVIN J. CANNING
JANE E. REMILLARD
DeANN FORAN SMITH
PETER C. LAURO
DEBRA J. MILASINIC, Ph.D.
DAVID J. RIKKERS
DAVID R. BURNS
JOHN S. CURRAN
SEAN D. DETWEILER
MEGAN E. WILLIAMS, Ph.D.

LISA M. DIROCCO
HATHAWAY P. RUSSELL *
MARIA LACCOTRIPE ZACHARAKIS, Ph.D.
VINCENT P. LOCCISANO
MERIDETH C. ARNOLD
DANIELLE L. HERRITT
EUIHOON LEE **

SENIOR COUNSEL
JAMES E. COCKFIELD

OF COUNSEL
JEREMIAH LYNCH
WILLIAM A. SCOFIELD, JR.
SIBLEY P. REPPERT
JEANNE M. DIGIORGIO
CYNTHIA L. KANIK, Ph.D.

PATENT AGENTS
THEODORE R. WEST
SHAYNE Y. HUFF, Ph.D.
CYNTHIA M. SOROOS
PETER W. DINI, Ph.D.
JONATHAN M. SPARKS, Ph.D.

TECHNICAL SPECIALISTS
CATHERINE M. BISHOP
JACOB G. WEINTRAUB
CRISTIN E. HOWLEY, Ph.D.
JILL ANN MELLO, Ph.D.

* Admitted in TX only
** Admitted in CT only

1645

#10

April 14, 2003

Commissioner for Patents
Washington, D.C. 20231

RECEIVED
APR 21 2003
TECH CENTER 1600/2900

Re: U.S. Patent Application No.: 09/828456
For: *Novel BLR Molecules Affecting Antibiotic Susceptibility*
Inventors: Levy, Stuart B. *et al.*
Filed: April 6, 2001
Our Ref. No.: PKZ-030

Dear Sir:

I enclose herewith for filing in the above-identified application the following:


1. Information Disclosure Statement (in duplicate);
2. PTO Form 1449;
3. Copies of references cited in PTO Form 1449 (12);
4. A copy of the International Search Report; and
5. A Return Postcard.

Please charge any necessary fees in connection with the enclosed statement to our Deposit Order Account No. 12-0080. For this purpose, a duplicate of this sheet is attached.


I hereby certify that this correspondence is deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on:


April 14, 2003

Date


Megan E. Williams, Esq., Reg. No. 43,270

Respectfully submitted,
LAHIVE & COCKFIELD, LLP


Megan E. Williams, Esq.
Registration No. 43,270
Attorney for Applicants



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of: Levy, Stuart B. *et al.*

Serial No.: 09/828456

Filed: April 6, 2001

For: *Novel BLR Molecules Affecting Antibiotic Susceptibility*

Attorney Docket No.: PKZ-030

Group Art Unit: 1645

Examiner: Hines, J.A.

RECEIVED
APR 21 2003
TECH CENTER 1600/2900

Commissioner for Patents
Washington, D.C. 20231


Certificate of First Class Mailing (37 CFR §1.8(a))

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on the date set forth below.

April 14, 2003

Date of Signature and of Mail Deposit

By:


Megan E. Williams, Esq.
Registration No. 43,270
Attorney for Applicants

INFORMATION DISCLOSURE STATEMENT

Dear Sir:


Applicants and their Attorney are aware of the following publications and information, listed on the attached PTO Form 1449, and in accordance with 37 CFR §1.97 hereby submit these publications for the Examiner's consideration. A copy of each cited publication is enclosed. A portion of the references cited on the PTO Form 1449 (A8, A10 and A12) were cited in an International Search Report mailed August 29, 2002 during the prosecution of PCT/US01/11363, which corresponds to the above-referenced application, and are enclosed as well.

This statement is not to be interpreted as a representation that the cited publications are material, that an exhaustive search has been conducted, or that no other relevant information exists. Nor shall the citation of any publication herein be construed *per se* as a representation that such publication is prior art. Moreover,

Applicants understand that the Examiner will make an independent evaluation of the cited publications.

In accordance with 37 CFR §1.97(c)(2) and §1.17(p), please charge the \$180.00 submission fee to our Deposit Order Account No. 12-0080. Please charge any necessary additional fees or credit any overpayments to our Deposit Order Account No. 12-0080.

Respectfully submitted,
LAHIVE & COCKFIELD, LLP


Megan E. Williams, Esq.
Registration No. 43,270
Attorney for Applicants

28 State Street
Boston, MA 02109
(617) 227-7400

Date: April 14, 2003

EAH/MEW/JMS/alf
Enclosures

APR 18 2003

Sheet 1 of 1

APPLICANT FACSIMILE OF FORM PTO-1449

U.S. DEPARTMENT OF
COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY DOCKET NO.

SERIAL NO.

REV 7-80

TRADEMARK OFFICE

PKZ-030

09/828456

LIST OF PUBLICATIONS CITED BY APPLICANT
(Use several sheets if necessary)

APPLICANT

Levy, Stuart B. et al.

FILING DATE

April 6, 2001

GROUP

1645

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILED DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO

OTHERS (including Author, Title, Date, Pertinent Pages, Etc.)

A1	Bentley, J. et al. "Cloning and sequence analysis of an <i>Escherichia coli</i> gene conferring bicyclomycin resistance." <i>Gene</i> . 1993 May 15;127(1):117-20
A2	Cohen, S.P. et al. "A multidrug resistance regulatory chromosomal locus is widespread among enteric bacteria." <i>J. Infect. Dis.</i> 1993 Aug;168(2):484-8
A3	Cullmann, W. <i>Anti Infective Drugs and Chemotherapy</i> 1994;12:36-43
A4	Garau, J. "Beta-lactamases: current situation and clinical importance." <i>Intensive Care Med.</i> 1994 Jul;20 Suppl 3:S5-9
A5	Guasch, J. F. et al. "A 17 kDa outer-membrane protein (Omp4) from <i>Serratia marcescens</i> confers partial resistance to bacteriocin 28b when expressed in <i>Escherichia coli</i> ." <i>Microbiology</i> . 1995 Oct;141 (Pt 10):2535-42
A6	Moir, D. T. et al. "Genomics and antimicrobial drug discovery." <i>Antimicrob. Agents Chemother.</i> 1999 Mar;43(3):439-46
A7	White, D.G. et al. "Inhibition of the multiple antibiotic resistance (<i>mar</i>) operon in <i>Escherichia coli</i> by antisense DNA analogs." <i>Antimicrob. Agents Chemother.</i> 1997 Dec;41(12):2699-704
A8	Wong, R.S.Y. et al. "'Intergenic' <i>blr</i> gene in <i>Escherichia coli</i> encodes a 41-residue membrane protein affecting intrinsic susceptibility to certain inhibitors of peptidoglycan synthesis." <i>Mol. Microbiol.</i> 2000 Jul;37(2):364-70
A9	GenBank Acc. No. : D90808 for E.coli genomic DNA, Kohara clone #317(36.6-36.9 min.)
A10	GenBank Acc. No. : D90807 for E.coli genomic DNA, Kohara clone #316(36.7-37.1 min.)
A11	GenBank Acc. No. : D90806 E.coli genomic DNA, Kohara clone #315(36.6-36.9 min.)
A12	GenBank Acc. No. : AE000258 for <i>Escherichia coli</i> K12 MG1655 section 148 of 400 of the complete genome
Examiner	
Date Considered	
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	